There was no increase in unresectable disease, new metastatic disease, or 30-day mortality associated with increasing delays.
The median rPFS was 24.0 months in the apalutamide arm and 16.6 months in the placebo arm.
There were numeric, but not significant, improvements in outcomes with letrozole.
Changes in weight and BMI were associated with disease-free and overall survival.
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
The nomogram proved more accurate than TNM staging for predicting 3-year and 5-year overall survival.
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
At the data cutoff, 70% of patients originally assigned to placebo had crossed over to the ivosidenib arm.
Patients with basal tumors did not derive a significant survival benefit from androgen signaling inhibitors.
Patients who received early palliative care had improvements in symptom control and mood over time.
